文献速递临床试验与 GCP真实世界研究与卫生经济

尼日利亚孕妇缺铁性贫血静脉铁剂与口服铁剂比较(IVON):随机混合效果-实施试验研究方案

Intravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women (IVON): study protocol for a randomised hybrid effectiveness-implementation trial.
PubMed 文献 · Trials · 2022-09-08

IVON试验是在尼日利亚卡诺和拉各斯10家卫生机构开展的非盲随机对照试验,采用混合1型效果-实施设计,计划纳入1056名孕20-32周、血红蛋白低于10g/dl的中重度贫血孕妇,按1:1随机接受单次1000mg静脉羧基麦芽糖铁或每日三次口服硫酸亚铁(每日元素铁195mg)至产后6周。主要结局为孕36周母亲贫血患病率和早产(<37周),同时评估静脉铁剂的接受度、可行性、保真度和成本效果。

要点

  • 针对尼日利亚孕妇缺铁性贫血,比较单次静脉羧基麦芽糖铁与标准口服硫酸亚铁的效果与安全性。
  • 计划纳入1056名孕20-32周、Hb<10g/dl的中重度贫血孕妇,1:1随机分组。
  • 主要结局为孕36周母亲贫血患病率与早产(<37周),并评估实施结局与成本效果。

核心结论

  • IVON试验可能为尼日利亚及类似资源有限、高负担地区整合和采用静脉铁剂治疗妊娠期贫血提供效果与实施证据。
  • 若发现有效,计划进一步开展探索不同静脉铁剂剂量的研究。

研究设计与样本

  • 非盲随机对照试验,采用混合1型效果-实施设计,在尼日利亚卡诺(北部)和拉各斯(南部)两州的10家卫生机构开展。
  • 计划纳入1056名孕20-32周、患中重度贫血(Hb<10g/dl)的孕妇,按1:1随机分为两组。
  • 干预组为入组时单次1000mg静脉羧基麦芽糖铁;对照组为每日三次口服硫酸亚铁(每日元素铁195mg),从入组至产后6周。
  • 主要结局为孕36周母亲贫血患病率和早产(<37周妊娠),按意向性治疗分析。
  • 在入组后4周、孕36周、分娩时和产后6周检测母亲全血细胞计数和铁代谢指标。

关键数值与推荐

  • 贫血诊断标准:Hb<10g/dl定义为中重度贫血。
  • 早产定义:<37周妊娠。
  • 静脉铁剂剂量:单次1000mg羧基麦芽糖铁。
  • 口服铁剂方案:硫酸亚铁每日三次,每日元素铁195mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaemia in pregnancy is highly prevalent in African countries. High-dose oral iron is the current recommended treatment for pregnancy-related iron deficiency anaemia (IDA) in Nigeria and other African countries. This oral regimen is often poorly tolerated and has several side effects. Parenteral iron preparations are now available for the treatment of IDA in pregnancy but not widely used in Africa. The IVON trial is investigating the comparative effectiveness and safety of intravenous ferric carboxymaltose versus oral ferrous sulphate standard-of-care for pregnancy-related IDA in Nigeria. We will also measure the implementation outcomes of acceptability, feasibility, fidelity, and cost-effectiveness for intravenous ferric carboxymaltose. METHODS: This is an open-label randomised controlled trial with a hybrid type 1 effectiveness-implementation design, conducted at 10 health facilities in Kano (Northern) and Lagos (Southern) states in Nigeria. A total of 1056 pregnant women at 20-32 weeks' gestational age with moderate or severe anaemia (Hb < 10g/dl) will be randomised 1:1 into two groups. The interventional treatment is one 1000-mg dose of intravenous ferric carboxymaltose at enrolment; the control treatment is thrice daily oral ferrous sulphate (195 mg elemental iron daily), from enrolment till 6 weeks postpartum. Primary outcome measures are (1) the prevalence of maternal anaemia at 36 weeks and (2) infant preterm birth (<37 weeks' gestation) and will be analysed by intention-to-treat. Maternal full blood count and iron panel will be assayed at 4 weeks post-enrolment, 36 weeks' gestation, delivery, and 6 weeks postpartum. Implementation outcomes of acceptability, feasibility, fidelity, and cost will be assessed with structured questionnaires, key informant interviews, and focus group discussions. DISCUSSION: The IVON trial could provide both effectiveness and implementation evidence to guide policy for integration and uptake of intravenous iron for treating anaemia in pregnancy in Nigeria and similar resource-limited, high-burden settings. If found effective, further studies exploring different intravenous iron doses are planned. TRIAL REGISTRATION: ISRCTN registry ISRCTN63484804 . Registered on 10 December 2020 Clinicaltrials.gov NCT04976179 . Registered on 26 July 2021 The current protocol version is version 2.1 (080/080/2021).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Afolabi BB, Babah OA, Akinajo OR, et al. Intravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women (IVON): study protocol for a randomised hybrid effectiveness-implementation trial. Trials. 2022. PMID: 36076211. doi:10.1186/s13063-022-06690-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。